AstraZeneca Vaccine to Continue Roll-Out Despite Reported Side-Effects

The Department of Health (DOH) and the Food and Drug Administration (FDA) said that the roll-out of the AstraZeneca COVID-19 Vaccine to continue amidst reported adverse effects.

This comes after the European Union (EU) has halted the use of the AstraZeneca vaccine after reports of blood clots on some patients.

“This has been decided as a precautionary measure, while they conduct a full investigation to determine causality between the vaccination and the reported adverse events following immunization,” said DOH in a press release.

The European Medicine Authority (EMA) has stated that there is no clear indication that the blood clots were caused by the vaccine as this is not listed as a side effect of the vaccine.

“The position of EMA’s safety committee PRAC is that the vaccine’s benefits continue to outweigh its risks and the vaccine can continue to be administered while investigation of cases of thromboembolic events is ongoing. PRAC is already reviewing all cases of thromboembolic events, and other conditions related to blood clots, reported post-vaccination with COVID-19 Vaccine AstraZeneca,” said the EMA.

Moreover, the DOH and FDA said that there is no reason to halt the roll-out of the said vaccine yet.

The public is assured that they are closely monitoring all deployed vaccines in the country. (ASC)